Welcome to the EGFR Patient Gateway Newsletter for February 2023.
The EGFR space continues to see lots of forward momentum. Scientists are working to understand targeted therapy resistance and to develop new drugs to combat it. Another approach includes increasing use of drug combinations. Researchers are also studying less common EGFR mutations. Finally, we are starting to see use of EGFR targeted therapy in earlier stages of disease.
Research News
Targeted Oncology
Adjuvant Osimertinib Shows Long-Term DFS Benefit in Resected EGFR-Mutated NSCLC
Published Feb 2, 2023
OncLive
Combinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment
Published Feb 2, 2023
Targeted Oncology
Amivantamab and Lazertinib as a Potential Option for EGFR-Mutant NSCLC
Published Feb 1, 2023
MDPI
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
Published Jan 29, 2023
EurekAlert!
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
Published Jan 19, 2023
MIMS.com
More evidence supports osimertinib for EGFR-mutated NSCLC
Published Dec 20, 2022
Resources for EGFR Survivors & Caregivers
- Connect with other survivors and caregivers through one of our friendly virtual meetups
- Read a Q&A with a world-class lung cancer expert as he discusses treatment options for patients who have tested positive for EGFR Exon 20 mutations
- Watch videos to learn about Shared-Decision Making, Self-Advocacy, Dealing with Financial Toxicity, and more… at the EGFR Patient Gateway.
If you need further assistance, please email us at support@lungevity.org. Our team is always here to assist you.
